VAP-1 Predicts Mortality in Patients With Type 2 Diabetes
Serum vascular adhesion protein-1 levels predict risk of cardiovascular and cancer mortality
MONDAY, March 14 (HealthDay News) -- The level of serum vascular adhesion protein-1 (VAP-1), a protein involved in inflammation, can predict the 10-year mortality risk among patients with type 2 diabetes, according to a study published in the March issue of Diabetes.
Hung-Yuan Li, M.D., of the National Taiwan University Hospital in Taipei, and colleagues investigated whether serum VAP-1 levels can be used to predict the 10-year survival of patients with type 2 diabetes. They measured serum VAP-1 levels in 661 participants, enrolled between July 1996 and June 2003, and followed up for an average of 10.4 years. Mortality data were verified by use of computerized death certificates.
The researchers found that individuals with serum VAP-1 in the highest tertile had an increased risk of all-cause mortality (hazard ratio [HR], 2.19) after adjusting for age, gender, smoking, history of cardiovascular disease, obesity, hypertension, hemoglobin A1C, duration of diabetes, total cholesterol, use of statins, abnormal ankle-brachial index, estimated glomerular filtration rate (eGFR), and proteinuria. Serum VAP-1 was an independent predictor of cardiovascular mortality (HR, 5.83), mortality from cardiovascular and diabetic causes (HR, 6.32), and cancer-related mortality (HR, 17.24). Mortality prediction was significantly improved by four variables: age, serum VAP-1, proteinuria, and eGFR.
"VAP-1 can independently predict 10-year all-cause mortality, cardiovascular mortality, and cancer-related mortality in subjects with type 2 diabetes. Our results showed that serum VAP-1 is a novel biomarker and improves risk prediction over and above the established risk factors for cardiovascular and cancer mortality in subjects with type 2 diabetes," the authors write.
Two authors disclosed financial ties with Biotie Therapies, which holds a patent for VAP-1.